New York’s cannabis regulator is turning patient buzz into hard data, launching the state’s first Office of Cannabis Management led observational study to see whether oral THC and CBD can ease everyday symptoms for adults living with inflammatory bowel disease (IBD). The pilot will enroll certified medical cannabis patients who have a clinically confirmed IBD diagnosis and track their symptom scores and quality-of-life measures while they use regulated oral cannabinoid products. State officials are pitching the project as a way to move beyond word-of-mouth and into evidence at a time when more patients are already reaching for cannabis to feel better.
In a press release from the Office of Cannabis Management, the agency announced the initiative and named Dr. Nakesha Abel as the study’s principal investigator. "Advancing comprehensive cannabis research is essential to expanding treatment options and supporting patient care," OCM Chief Medical Officer Dr. Junella Chin said in the release. The office described the effort as a first-of-its-kind, regulator-led observational study designed to give providers and policymakers real-world patient data rather than guesswork.
Who’s running the study and where
The Office plans to work with licensed medical dispensaries so that enrolled patients can access tested products, and coverage of the rollout notes partnerships with Vireo Health and Green Thumb Industries’ RISE dispensary brand, as reported by The Marijuana Herald. Those partners are expected to keep study products inside New York’s regulated medical cannabis system while researchers collect patient-reported outcomes. Organizers say the setup is meant to make participation realistic for patients in multiple regions of the state rather than just those near a single research center.
Who can join and what they'll take
Prospective participants must be at least 18 years old and have a clinically confirmed diagnosis of inflammatory bowel disease, according to reporting by amNewYork. The outlet reports that enrolled patients will be asked to avoid marijuana in smokable form for the length of the study and instead take oral doses of CBD and THC, generally in the 10 to 35 mg range each day. Those who qualify and sign up are expected to receive vouchers that cover the cost of their medical cannabis during the study period, the reporting notes.
Why researchers say it matters
Inflammatory bowel disease is far from rare. The Crohn’s & Colitis Foundation estimates that roughly 3 million people in the United States are living with Crohn’s disease or ulcerative colitis. The conditions also carry a hefty price tag. According to the Centers for Disease Control and Prevention, annual U.S. health care costs for IBD totaled about $8.5 billion in 2018, with prescribed medicines accounting for roughly 71 percent of that amount.
What the science shows so far
Existing randomized trials and observational studies on cannabis for IBD are limited and mixed. Systematic reviews have found some short-term improvements in patient-reported symptoms and quality of life, but not much consistent evidence that cannabinoids tamp down objective markers of intestinal inflammation. A recent meta-analysis in Inflammatory Bowel Diseases concluded that cannabinoids may help symptom scores, while stressing that larger and better-controlled studies are needed to clarify both risks and benefits.
For patients and providers eyeing the New York study, the Office of Cannabis Management has posted information on participating dispensaries and study materials on its site. OCM’s list of participating medical cannabis dispensaries includes details on how and where to enroll. Patients are advised to talk with their certifying health care provider before making any changes to an existing treatment plan.
